Rare, Genetic Form of Dementia Described
The discovery of a new, genetic form of dementia uncovers a pathway of tau protein build up in the brain that could be targeted for new therapies.
Related Articles
Standardizing CGT Supply Chain Management
The risk of a wrong product being dosed to a patient is exacerbated by a lack of standardization within the cell and gene therapy industry.
Panning the Golden Batch
By monitoring critical metabolic parameters, a path can be mapped out to create golden batches, which meet or exceed all of the critical process parameters.
Overcoming Cell Therapy CMC Challenges
Bioprocessing technology has a role to play in helping developers exert greater control over production processes.
Addressing the Puzzle of Bispecific Antibody Manufacturing
By doing early screening, it’s possible for researchers to accelerate process development and move to commercial bsAb manufacturing.
Key Drivers of AI Drug Discovery
At GEN’s inaugural virtual summit on The State of AI in Drug Discovery, experts evaluated the evolution, opportunities, and challenges of AI-enhanced drug development.
Wrapping up 2024: GEN’s Editors Reflect on the Past Year and Look ahead to 2025
In this episode of GEN Live, members of the editorial team, Uduak Thomas and Alex Philippidis, will join host Dr. Julianna LeMieux, Deputy Editor-in-Chief of…
Insilico Details AI-Designed IBD Candidate’s Path to Nomination
ISM5411 is designed to directly regulate the intestinal immune microenvironment so that the drug simultaneously reduces the gut inflammation seen in IBD while also promoting…
Ten Companies to Watch in AI Drug Discovery
In AI-based drug discovery—a field benefiting from a cumulative investment of $60 billion—the leaders are making real progress toward approved therapies.
Insilico Details AI-Designed IBD Candidate’s Path to Nomination
ISM5411 is designed to directly regulate the intestinal immune microenvironment so that the drug simultaneously reduces the gut inflammation seen in IBD while also promoting…
Tasca Raises $52 Million to Target Novel Lipid-Bound Protein Pocket in Cancer, Other Diseases
The company will develop a pipeline of small molecule inhibitors that target a unique lipid-binding pocket on proteins.